Vaccination coverage among paediatric onco-haematological patients: an Italian cross-sectional study.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
04 03 2021
Historique:
pubmed: 28 8 2020
medline: 24 6 2021
entrez: 27 8 2020
Statut: ppublish

Résumé

Children with onco-hematological diseases are at increased risk of infection. However, this risk can in part be controlled or reduced using currently available vaccines. Despite available evidence, in patients diagnosed with a hematological or oncological disease the vaccination schedule is often inappropriately discontinued. In this study we evaluated whether the diagnosis of an oncological or hematological disease is a determinant of noncompliance with recommended vaccinations.The study was carried out between March and April 2019. The population was composed of a convenience sample of 228 children cared for in the Pediatric Oncology Department and Pediatric Hematology Department of the Policlinico Giovanni XXIII Pediatric Hospital (Bari, Italy) from 2005 to 2015. Information on the immunization status of the patients was obtained from the Apulia regional immunization database (GIAVA). A post-diagnosis adherence score was calculated.The vaccination coverage was 87.7% for the DTaP-IPV-Hep B-Hib vaccine (3 doses), 68.7% for the pneumococcal vaccine (3 doses), 75.8% for the MMR vaccine (2 doses) and 75.1% for the varicella vaccine (2 doses). The average age at vaccination was older than that recommended by the National Vaccination Plan. A diagnosis of oncological disease and an older age at enrollment were risk factors for missing vaccinations. These results showed that the overall vaccination status of pediatric onco-hematological patients is suboptimal. Improving provider communication and establishing the hospital as the primary environment for vaccine administration may lead to better vaccination compliance in this group.

Identifiants

pubmed: 32845796
doi: 10.1080/21645515.2020.1797367
pmc: PMC7993150
doi:

Substances chimiques

Haemophilus Vaccines 0
Measles-Mumps-Rubella Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

818-823

Références

Vaccine. 2018 Jun 7;36(24):3541-3554
pubmed: 29426658
Am J Infect Control. 2018 Jan;46(1):e9-e11
pubmed: 29167031
Biomed Res Int. 2014;2014:707691
pubmed: 24868544
J Pediatr Hematol Oncol. 2013 Jul;35(5):348-55
pubmed: 23619106
Bone Marrow Transplant. 2017 Dec;52(12):1681-1683
pubmed: 28920950
Am J Infect Control. 2017 Aug 1;45(8):e87-e89
pubmed: 28410825
J Clin Immunol. 2015 Nov;35(8):696-726
pubmed: 26482257
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006484
pubmed: 19370636
Vaccine. 2012 Jul 20;30(34):5172-8
pubmed: 21414380
Semin Hematol. 2009 Jul;46(3):313-24
pubmed: 19549582
Acta Haematol. 2008;119(1):1-7
pubmed: 18176072
J Allergy Clin Immunol. 2014 Apr;133(4):961-6
pubmed: 24582311
Infect Drug Resist. 2019 Sep 12;12:2839-2851
pubmed: 31571940
Clin Infect Dis. 2014 Feb;58(3):309-18
pubmed: 24421306
Vaccine. 2011 Apr 5;29(16):2825-33
pubmed: 21345379
Hum Vaccin Immunother. 2013 May;9(5):1158-62
pubmed: 23324619
Clin Infect Dis. 2007 Mar 1;44(5):635-42
pubmed: 17278052
Pediatrics. 2011 May;127 Suppl 1:S127-33
pubmed: 21502238
J Cancer Surviv. 2020 Oct;14(5):757-767
pubmed: 32458248
Vaccine. 2014 Aug 27;32(38):4860-5
pubmed: 24262311
Pediatrics. 2002 Jan;109(1):124-9
pubmed: 11773551
Vaccine. 2016 Dec 20;34(52):6700-6706
pubmed: 27810314
Lancet Oncol. 2019 Sep;20(9):1211-1225
pubmed: 31371206
Hum Vaccin Immunother. 2019;15(3):643-644
pubmed: 30352002
Haemophilia. 2019 Jul;25(4):656-667
pubmed: 30990961
Biol Blood Marrow Transplant. 2017 Sep;23(9):1437-1446
pubmed: 28495643
J Spec Pediatr Nurs. 2017 Jan;22(1):
pubmed: 28074595

Auteurs

Paola Giordano (P)

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.

Nicola Santoro (N)

Paediatric Oncology Department, Bari Policlinico General Hospital, Bari, Italy.

Pasquale Stefanizzi (P)

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.

Stefano Termite (S)

Public Health Department, Brindisi Health Trust, ASL Brindisi, Dipartimento di Prevenzione, Brindisi, Italy.

Sara De Nitto (S)

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.

Francesco Paolo Bianchi (FP)

Public Health Department, Brindisi Health Trust, ASL Brindisi, Dipartimento di Prevenzione, Brindisi, Italy.

Paola Carmela Corallo (PC)

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.

Giuseppe Lassandro (G)

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.

Silvio Tafuri (S)

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH